NasdaqGM - Delayed Quote USD

Keen Vision Acquisition Corporation (KVACU)

11.30

0.00

(0.00%)

At close: April 23 at 4:00:00 PM EDT

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that updated results from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology, were presented at the 2025 HFpEF Summit held March 19-

GlobeNewswire last month

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluat

GlobeNewswire last month

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Completes Patient Dosing for Heart Failure Treatment

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024. “We are very excited and encouraged […]

Exec Edge last month

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accou

GlobeNewswire last month

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac disease modeling and therapeutic screening, including both drug candidates and gene editing approachesDriving Innovation: This installation paves the way for future co-development projects with UMC Utrecht, advancing human-based research and cardiac regenerative technologies BOSTON and UTRECHT, Nether

GlobeNewswire 2 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera, Inc. to Participate in Two Upcoming Investor Conferences

SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two upcoming investor conferences in February 2025 as follows: Oppenheimer 35th Annual Healthcare Life Sciences Conference: presentation at 10:40 am ET on February 11th and available to host investor meetingsBIO CEO & Investor Conference: available for meetings on February 10th and 11th A live audio webcast o

GlobeNewswire 2 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio’s cloud-based Pulse™ analytics, enabling smart and accelerated cardiac drug screening.Industry-First Capabilities Combined: Medera’s Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and FTD applications. As a pi

GlobeNewswire 4 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing protocols, setting a new benchmark for human-based cardiac screeningLatest enhanced 96-well technology enables rapid, high-throughput screening on bioengineered human heart tissues, with significant cost and efficiency gains BOSTON and GOTHENBURG, Sweden, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera

GlobeNewswire 4 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Inc. ("Medera"), a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches, announced today the publication of a new study in the peer-reviewed journal Pharmacological Research (volume 209). This study, entitled "Enhanced Drug Classification Using Machine Learning with Multiplexed Cardiac Contractility Assays," demonstrates how Novoheart, Medera's wholly-owned preclinical subsidia

PR Newswire 5 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-dose). Following the recommendation of the Data Safety Monitoring Board (DSMB), dosing has begun for patients in Cohort B (high-dose). This Phase 1/2a clinical trial evaluates the first-in-human cardiac gene therapy candidate SRD-002 for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).

PR Newswire 6 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

By Karen Roman Biotechnology company Medera Inc. said it entered a definitive merger agreement with Keen Vision Acquisition Corp. (Nasdaq: KVAC), with the combined company having an implied initial enterprise value of approximately $622.6 million. The transaction will close in the fourth quarter and the combined company will be called Medera Inc., both firms said […]

Exec Edge 7 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Keen Vision Acquisition Corporation ("KVAC") (Nasdaq: KVAC, KVACW) and Medera Inc., ("Medera"), a clinical-stage biotechnology company, announced today that they have entered into a definitive merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company is to be named Medera Inc.

PR Newswire 7 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW
With 61% ownership, Keen Vision Acquisition Corporation (NASDAQ:KVAC) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, Keen Vision Acquisition's stock price might be...

Simply Wall St. 9 months ago

KVAC
+0.18%

KVACU
0.00%

KVACW

Performance Overview

Return	KVACU	S&P 500 (^GSPC)
YTD	+2.82%	-3.31%
1-Year	+7.41%	+12.29%
3-Year	+11.88%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Keen Vision Acquisition Corporation (KVACU)

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction

Medera Completes Patient Dosing for Heart Failure Treatment

Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera, Inc. to Participate in Two Upcoming Investor Conferences

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp.

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

With 61% ownership, Keen Vision Acquisition Corporation (NASDAQ:KVAC) boasts of strong institutional backing

Performance Overview